Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gremubamab (MEDI3902) for prevention of P. aeruginosa pneumonia in ventilated patients
NCT02696902Phase 2Completed
- Sponsor
- MedImmune
- Start
- Mar 2016
- Primary completion
- Dec 2019
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of gremubamab in Pseudomonas aeruginosa pneumonia, sponsored by MedImmune. Started Mar 2016; status: completed.
02
Drugs
gremubamab
03
Conditions
Pseudomonas aeruginosa pneumonia
Beyond the preview
Go deeper on NCT02696902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696902.